2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Print

Mini-Oral Session

[MO31] Mini-Oral Session 31　Clinical Trial Facilitation Program 1（Trial in Progress）

Sat. Feb 19, 2022 8:20 AM - 9:10 AM Room 3 (Annex 2, 1F, Kyoto International Conference Center)

Chair：Tetsuya Kusumoto（Department of Gastroenterological Surgery / Clinical Research Institute Cancer Research Division），Hideo Baba（Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University）

[MO31-2] Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer

○Hidehito Horinouchi1, J.W. Goldman2, F. Moiseenko3, I. Cicin4, E. Filippova5, J. Bar6, P. Tomasini7, C. Ocampo8, D. Sullivan8, D. Maag8, M. Motwani8, J. Jin8, D.R. Camidge9 (1.National Cancer Center Hospital, 2.David Geffen School of Medicine at UCLA, Los Angeles, CA/United States of America, 3.St. Petersburg City Cancer Center, St. Petersburg/Russian Federation, 4.Trakya University Medical Center, Edirne/Turkey, 5.Center of Palliative Medicine De Vita, St. Petersburg/Russian Federation, 6.Sheba Medical Center, Ramat Gan/lsrael, 7.Aix Marseille Univ, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille/France, 8.AbbVie, Inc., North Chicago, IL/United States of America, 9.University of Colorado Cancer Center, Aurora, CO/United States of America)

Abstract password authentication.
The password can be found on page 27 of the program book.

Password